280 related articles for article (PubMed ID: 30475668)
1. Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial.
Ruhstaller T; Giobbie-Hurder A; Colleoni M; Jensen MB; Ejlertsen B; de Azambuja E; Neven P; Láng I; Jakobsen EH; Gladieff L; Bonnefoi H; Harvey VJ; Spazzapan S; Tondini C; Del Mastro L; Veyret C; Simoncini E; Gianni L; Rochlitz C; Kralidis E; Zaman K; Jassem J; Piccart-Gebhart M; Di Leo A; Gelber RD; Coates AS; Goldhirsch A; Thürlimann B; Regan MM;
J Clin Oncol; 2019 Jan; 37(2):105-114. PubMed ID: 30475668
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial.
Albain KS; Barlow WE; Ravdin PM; Farrar WB; Burton GV; Ketchel SJ; Cobau CD; Levine EG; Ingle JN; Pritchard KI; Lichter AS; Schneider DJ; Abeloff MD; Henderson IC; Muss HB; Green SJ; Lew D; Livingston RB; Martino S; Osborne CK;
Lancet; 2009 Dec; 374(9707):2055-2063. PubMed ID: 20004966
[TBL] [Abstract][Full Text] [Related]
3. Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98.
Kensler KH; Regan MM; Heng YJ; Baker GM; Pyle ME; Schnitt SJ; Hazra A; Kammler R; Thürlimann B; Colleoni M; Viale G; Brown M; Tamimi RM
Breast Cancer Res; 2019 Feb; 21(1):30. PubMed ID: 30795773
[TBL] [Abstract][Full Text] [Related]
4. Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98.
Koeberle D; Thuerlimann B
Breast Cancer Res Treat; 2007; 105 Suppl 1(Suppl 1):55-66. PubMed ID: 17912636
[TBL] [Abstract][Full Text] [Related]
5. Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial.
Metzger Filho O; Giobbie-Hurder A; Mallon E; Gusterson B; Viale G; Winer EP; Thürlimann B; Gelber RD; Colleoni M; Ejlertsen B; Debled M; Price KN; Regan MM; Coates AS; Goldhirsch A
J Clin Oncol; 2015 Sep; 33(25):2772-9. PubMed ID: 26215945
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant endocrine monotherapy for postmenopausal early breast cancer patients with hormone-receptor positive: a systemic review and network meta-analysis.
Yu Z; Guo X; Jiang Y; Teng L; Luo J; Wang P; Liang Y; Zhang H
Breast Cancer; 2018 Jan; 25(1):8-16. PubMed ID: 28755088
[TBL] [Abstract][Full Text] [Related]
7. Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial.
Johnston S; Puhalla S; Wheatley D; Ring A; Barry P; Holcombe C; Boileau JF; Provencher L; Robidoux A; Rimawi M; McIntosh SA; Shalaby I; Stein RC; Thirlwell M; Dolling D; Morden J; Snowdon C; Perry S; Cornman C; Batten LM; Jeffs LK; Dodson A; Martins V; Modi A; Osborne CK; Pogue-Geile KL; Cheang MCU; Wolmark N; Julian TB; Fisher K; MacKenzie M; Wilcox M; Huang Bartlett C; Koehler M; Dowsett M; Bliss JM; Jacobs SA
J Clin Oncol; 2019 Jan; 37(3):178-189. PubMed ID: 30523750
[TBL] [Abstract][Full Text] [Related]
8. Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancer.
Mamounas EP; Bandos H; Rastogi P; Lembersky BC; Jeong JH; Geyer CE; Fehrenbacher L; Chia SK; Brufsky AM; Walshe JM; Soori GS; Dakhil SR; Wade JL; McCarron EC; Swain SM; Wolmark N
J Natl Cancer Inst; 2023 Nov; 115(11):1302-1309. PubMed ID: 37184928
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Follow-Up of the Intergroup Exemestane Study.
Morden JP; Alvarez I; Bertelli G; Coates AS; Coleman R; Fallowfield L; Jassem J; Jones S; Kilburn L; Lønning PE; Ortmann O; Snowdon C; van de Velde C; Andersen J; Del Mastro L; Dodwell D; Holmberg S; Nicholas H; Paridaens R; Bliss JM; Coombes RC
J Clin Oncol; 2017 Aug; 35(22):2507-2514. PubMed ID: 28467729
[TBL] [Abstract][Full Text] [Related]
10. Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study.
Nuzzo F; Gallo C; Lastoria S; Di Maio M; Piccirillo MC; Gravina A; Landi G; Rossi E; Pacilio C; Labonia V; Di Rella F; Bartiromo A; Buonfanti G; De Feo G; Esposito G; D'Aniello R; Maiolino P; Signoriello S; De Maio E; Tinessa V; Colantuoni G; De Laurentiis M; D'Aiuto M; Di Bonito M; Botti G; Giordano P; Daniele G; Morabito A; Normanno N; de Matteis A; Perrone F
Ann Oncol; 2012 Aug; 23(8):2027-2033. PubMed ID: 22412041
[TBL] [Abstract][Full Text] [Related]
11. A randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer.
Shiba E; Yamashita H; Kurebayashi J; Noguchi S; Iwase H; Ohashi Y; Sasai K; Fujimoto T
Breast Cancer; 2016 May; 23(3):499-509. PubMed ID: 25655898
[TBL] [Abstract][Full Text] [Related]
12. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.
; Davies C; Godwin J; Gray R; Clarke M; Cutter D; Darby S; McGale P; Pan HC; Taylor C; Wang YC; Dowsett M; Ingle J; Peto R
Lancet; 2011 Aug; 378(9793):771-84. PubMed ID: 21802721
[TBL] [Abstract][Full Text] [Related]
13. Concordance of real-world versus conventional progression-free survival from a phase 3 trial of endocrine therapy as first-line treatment for metastatic breast cancer.
Huang Bartlett C; Mardekian J; Cotter MJ; Huang X; Zhang Z; Parrinello CM; Bourla AB
PLoS One; 2020; 15(4):e0227256. PubMed ID: 32315295
[TBL] [Abstract][Full Text] [Related]
14. Symptoms of endocrine treatment and outcome in the BIG 1-98 study.
Huober J; Cole BF; Rabaglio M; Giobbie-Hurder A; Wu J; Ejlertsen B; Bonnefoi H; Forbes JF; Neven P; Láng I; Smith I; Wardley A; Price KN; Goldhirsch A; Coates AS; Colleoni M; Gelber RD; Thürlimann B;
Breast Cancer Res Treat; 2014 Jan; 143(1):159-69. PubMed ID: 24305979
[TBL] [Abstract][Full Text] [Related]
15. Identifying treatment effect heterogeneity in clinical trials using subpopulations of events: STEPP.
Lazar AA; Bonetti M; Cole BF; Yip WK; Gelber RD
Clin Trials; 2016 Apr; 13(2):169-79. PubMed ID: 26493094
[TBL] [Abstract][Full Text] [Related]
16. Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5.
Dowsett M; Sestak I; Regan MM; Dodson A; Viale G; Thürlimann B; Colleoni M; Cuzick J
J Clin Oncol; 2018 Jul; 36(19):1941-1948. PubMed ID: 29676944
[TBL] [Abstract][Full Text] [Related]
17. Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor-Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance).
Hwang ES; Hyslop T; Hendrix LH; Duong S; Bedrosian I; Price E; Caudle A; Hieken T; Guenther J; Hudis CA; Winer E; Lyss AP; Dickson-Witmer D; Hoefer R; Ollila DW; Hardman T; Marks J; Chen YY; Krings G; Esserman L; Hylton N
J Clin Oncol; 2020 Apr; 38(12):1284-1292. PubMed ID: 32125937
[TBL] [Abstract][Full Text] [Related]
18. Are we there yet? Optimal duration of endocrine therapy in women with postmenopausal early-stage hormone receptor-positive breast cancer.
Symonds LK; Davidson NE
J Natl Cancer Inst; 2023 Nov; 115(11):1240-1242. PubMed ID: 37480258
[No Abstract] [Full Text] [Related]
19. Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial.
Ejlertsen B; Aldridge J; Nielsen KV; Regan MM; Henriksen KL; Lykkesfeldt AE; Müller S; Gelber RD; Price KN; Rasmussen BB; Viale G; Mouridsen H;
Ann Oncol; 2012 May; 23(5):1138-1144. PubMed ID: 21986093
[TBL] [Abstract][Full Text] [Related]
20. Insights adjusting for non-adherence in randomized clinical trials: a reanalysis of an adjuvant trial of tamoxifen duration in early breast cancer.
Giudici F; Pistilli B; Vaz-Luis I; Karimi M; Delaloge S; Bachelot T; Michiels S; Bardet A
Br J Cancer; 2023 Oct; 129(9):1516-1523. PubMed ID: 37697030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
